- Home
- UHT vs ANNX Comparison
UHT vs ANNX Comparison
Compare UHT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- ANNX
- Stock Information
- Founded
- UHT 1986
- ANNX 2011
- Country
- UHT United States
- ANNX United States
- Employees
- UHT N/A
- ANNX N/A
- Industry
- UHT Real Estate Investment Trusts
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- ANNX Health Care
- Exchange
- UHT Nasdaq
- ANNX Nasdaq
- Market Cap
- UHT 583.6M
- ANNX 622.3M
- IPO Year
- UHT N/A
- ANNX 2020
- Fundamental
- Price
- UHT $42.25
- ANNX $7.36
- Analyst Decision
- UHT
- ANNX Strong Buy
- Analyst Count
- UHT 0
- ANNX 7
- Target Price
- UHT N/A
- ANNX $15.80
- AVG Volume (30 Days)
- UHT 58.6K
- ANNX 1.3M
- Earning Date
- UHT 10-24-2024
- ANNX 11-19-2024
- Dividend Yield
- UHT 6.91%
- ANNX N/A
- EPS Growth
- UHT 3.98
- ANNX N/A
- EPS
- UHT 1.31
- ANNX N/A
- Revenue
- UHT $99,899,000.00
- ANNX N/A
- Revenue This Year
- UHT N/A
- ANNX N/A
- Revenue Next Year
- UHT N/A
- ANNX N/A
- P/E Ratio
- UHT $32.07
- ANNX N/A
- Revenue Growth
- UHT 3.43
- ANNX N/A
- 52 Week Low
- UHT $32.27
- ANNX $2.05
- 52 Week High
- UHT $47.30
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- UHT 53.92
- ANNX 55.04
- Support Level
- UHT $38.99
- ANNX $6.85
- Resistance Level
- UHT $40.98
- ANNX $7.63
- Average True Range (ATR)
- UHT 1.10
- ANNX 0.29
- MACD
- UHT 0.27
- ANNX -0.06
- Stochastic Oscillator
- UHT 92.47
- ANNX 57.30
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio which is located throughout the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.